For Immediate Release

30 January 2006

Contact: CAUSE Marketing, LLC

Media Contact: Corin Walson

Office: 714/ 921.6925

Mobile: 714/ 865.4147

Email: cwalson@4causemarketing.com

FIBRONOL STUDY IMPACTS FIBROMYALGIA

New natural supplement improves sleep and overall condition of fibromyalgia, study shows

ORANGE, Calif----23 January 2006---What would you do if you got an extra 1.6 hours of sleep? Go for a walk? Head to the gym? Spend more time with your family and friends?

An extra hour or two of sleep may not sound like much, but for people suffering from fibromyalgia, where sleep disorders are one of the main symptoms, it can mean a world of difference in improved health and well being. Studies have shown that with a good night’s rest, people with fibromyalgia experience less pain and fewer symptom flare-ups.

The National Fibromyalgia Association today announced the results of a clinical study by the makers of a new supplement, Fibronol®. The study shows that, after taking Fibronol for eight weeks, participants gained an average of 1.6 more hours of sleep a night, with an 80% improvement in the soundness of sleep.

In November 2005, an abstract summarizing the Fibronol Phase I-a clinical trial results reported the following additional symptom improvements:

• 39% improvement in overall condition
• 71% gain in energy
• 31% reduction in perceived pain levels
• 30% reduction in fatigue

Classified as a natural food-based product, Fibronol is a  safe, effective and natural supplement clinically proven to provide significant improvements in treating the symptoms of fibromyalgia.

According to Trey MacPhee, President of Fibronol LLC, the  primary source of Fibronol’s effectiveness in relieving fibromyalgia symptoms lies in utilizing the multiple and powerful healing properties of SEANOL-F.   An ocean-based polyphenol extract from brown algae, SEANOL-F has uniquely strong anti-oxidant and anti-inflammatory properties that  promote cardiovascular health and protection.

“Since there are very few products offering effective multi-symptom relief for fibromyalgia patients, it is encouraging news for the fibromyalgia community that the makers of Fibronol spent the time and money to put their product through a rigorous clinical study,” said Lynne Matallana, president and founder of the National Fibromyalgia Association.

MacPhee said his company waited until clinical trial results verified the safety and efficacy of their product before offering it to consumers.  He also said “The study confirmed that Fibronol delivers  unprecedented multi-symptom relief to people with fibromyalgia and as a result this product will benefit  many underserved fibromyalgia patients.”

The company presently is undertaking further product research, including whether additional symptom relief can be achieved  when Fibronol is supplemented with another natural supplement, FibroBoost.

For a complete text of the clinical abstract, visit the company’s website at: www.fibronol.com. 

For more information about the National Fibromyalgia Association, go to www.FMaware.org or call 714-921-0150.

---#---